BFRIW 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-13

• The estimated remediation cost with respect to the ITC Matter of $0.5 million, representing management’s best estimate within a range of $0.4 million to $0.6 million, has been recognized as a $0.4 million charge to operating expenses within patent remediation expense and a $0.1 million charge to cos…

• We conduct all clinical trials for Ameluz® in the United States through Biofrontera Discovery GmbH, allowing for more effective cost management and direct oversight of trial efficiency. Our R&D expenses include costs directly attributable to the clinical development of Ameluz®, including personnel-r…

• The following table summarizes our results of operations for the three months ended June 30:

• Selling, general and administrative, related party 41 69 (28)

• Net product revenue for the three months ended June 30, 2026 was $12.0 million, an increase of $3.0 million, or 32.9%, compared to the three months ended June 30, 2025. The increase was primarily attributable to higher Ameluz® net sales, reflecting $2.6 million or 30.0% growth in unit volume. Of the…

相对上期删除的文字 · 来源:10-Q · 2026-05-14

• Effective June 1, 2024, we took control of all clinical trials for Ameluz in the United States, allowing for more effective cost management and direct oversight of trial efficiency. Our R&D expenses include costs directly attributable to the clinical development of Ameluz, including personnel-relate…

• Comparison of the Three Months ended March 31, 2026 and 2025

• The following table summarizes our results of operations for the three months ended March 31, 2026 and 2025:

• Net product revenue for the three months ended March 31, 2026 was $10.1 million, an increase of $1.5 million, or 17.4%, compared to the three months ended March 31, 2025. The increase was primarily attributable to higher Ameluz® net sales, reflecting 15.9% growth in unit volume, as well as the full …

• Selling, general and administrative expenses for the three months ended March 31, 2026 were $11.0 million, an increase of $2.3 million, or 27.1%, compared to the three months ended March 31, 2025. Selling and marketing expenses increased $0.8 million, reflecting the full deployment of the direct sal…